Targeted Therapy for Advanced Prostate Cancer Receives FDA Approval

Add a Comment By Memorial Sloan-Kettering   |   Friday, August 31, 2012 Enzalutamide, a targeted therapy co-invented by a Memorial Sloan-Kettering investigator, has received FDA approval for the treatment of men with metastatic prostate cancer. read more

Read the article:
Targeted Therapy for Advanced Prostate Cancer Receives FDA Approval

Share and Enjoy:
  • Print
  • Digg
  • StumbleUpon
  • Facebook
  • Yahoo! Buzz
  • Twitter
  • Google Bookmarks
  • Add to favorites
  • email
  • LinkedIn
  • RSS
  • Tumblr
Share